OUR SCIENCE & TECHNOLOGY
. . . . . .
Respira AOS™ Dry-Powder Inhaler Technology
Our products target improved patient experience and efficient pulmonary drug delivery.
. . . . . .
“True target” drug delivery as needed (PRN)
RT234 (vardenafil inhalation powder) and Axial Oscillating Sphere Dry Powder Inhaler (AOS DP)
Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity.
Respira can deliver pure drug, carrier-blended, and particle-engineered formulations over a wide range of drug-powder payloads and molecule types.
Scientific Publications
. . . . . .
Acute Hemodynamic Improvement in Chronic Pulmonary Arterial Hypertension on Dual Therapy Following RT234-PAH Inhalation
Chest Annual Meeting 2020
October 18–21, 2020
Keogh A, Dwyer N, Kotlyar E, Kaye D, Maurer M, Weers J, Parsley E.
Safety and Pharmacokinetics of Vardenafil Inhalation Powder (RT234-PAH) Following Oral Inhalation in Healthy Adult Volunteers
Chest Annual Meeting 2020
October 18–21, 2020
Parsley EL, Weers J, Tarara, T, Eldon M, TepperJ, Maurer M.
Design of a Capsule-Based Dry Powder Inhaler for PAH Patients: The AOS™ DPI
Formulation & Delivery Series U.S.: Virtual.
September 29-30, 2020
Lyons S, Weers J.
